Summit Therapeutics Analyst Price Targets - Benzinga

Summit Therapeutics Inc

SMMTNASDAQ

Trade with Public

Trade with Public

$17.13

-0.46-2.62%

最終更新: Oct 13, 8:51 AM

$16.80

-0.79-4.49%

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Summit Therapeutics Analyst Price Targets - Benzinga

Summit Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Summit Therapeutics (SMMT).

Price Target Range — 12 Quarters

Analyst Consensus — 17 Analysts

3S.Buy

10Buy

4Hold

Consensus RatingBuy# Analysts17Avg. Consensus PT$32Upside to Avg. PT+89.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 1, 2026	Barclays	Etzer Darout	PT Raise	Equal-Weight	$18→$20
Sep 29, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$40→$43
Sep 23, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Neutral	—
Sep 9, 2026	Jefferies	Faisal Khurshid	Upgrade	Hold→Buy	$15→$25
Aug 26, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Neutral	—
Aug 25, 2026	Bernstein	Jeffrey Walch	Upgrade	Underperform→Market Perform	$10→$12
Aug 18, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Neutral	—
Aug 12, 2026	Leerink Partners	Daina Graybosch	Upgrade	Underperform→Market Perform	$12→$13
Jul 24, 2026	Stifel	Dara Azar	PT Cut	Buy	$45→$38
Jul 24, 2026	Guggenheim	Brad Canino	PT Cut	Buy	$40→$38
Jul 23, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Neutral	—
May 22, 2026	Bernstein	Jeffrey Walch	Initiate	Underperform	$8
May 22, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Downgrade	Buy→Neutral	—
May 4, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$30→$23
May 1, 2026	Piper Sandler	Kelsey Goodwin	PT Cut	Neutral	$17→$16
Apr 8, 2026	Stifel	Dara Azar	Initiate	Buy	$45
Mar 16, 2026	Jefferies	Clara Dong	Downgrade	Buy→Hold	$42→$15
Feb 24, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$40→$30
Feb 2, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$40
Jan 30, 2026	Citizens	Reni J. Benjamin	Maintained	Market Outperform	$40

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Equal-Weight on Summit Therapeutics, Raises Price Target to $20

Barclays analyst Etzer Darout maintains Summit Therapeutics (NASDAQ:SMMT) with a Equal-Weight and raises the price target from $18 to $20.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Summit Therapeutics, Raises Price Target to $43

Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from $40 to $43.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Summit Therapeuticsto Neutral

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) from Neutral to Neutral.

Benzinga Newsdesk

PRO
Jefferies Upgrades Summit Therapeutics to Buy, Raises Price Target to $25

Jefferies analyst Faisal Khurshid upgrades Summit Therapeutics (NASDAQ:SMMT) from Hold to Buy and raises the price target from $15 to $25.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Summit Therapeuticsto Neutral

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) from Neutral to Neutral.

Benzinga Newsdesk

This AMD Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Top analysts upgraded Fluence Energy, Dynatrace, and Advanced Micro Devices, Check out their ratings.

Avi Kapoor